British cell therapy specialist Rexgenero has bought all the key assets of Paris-based immunotherapy company aratinga.bio, a pre-clinical-stage firm developing an off-the-shelf Car-T cell therapy.
Founded in 2017, aratinga.bio has a novel approach which allows for in vivo targeting and transduction of T cells.
All assets of the firm will be transferred to a newly-created French subsidiary of Rexgenero.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze